Xiaowen Zhai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaowen Zhai has a total of 264 co-authors. Here are the top co-authors by number of shared publications:
Hongsheng Wang
Department of Hematology and Oncology, Children's Hospital of Fudan University, Shanghai 201102, China
19 shared publicationsXiaowen Qian
Department of Hematology, Children’s Hospital of Fudan University, National Children’s Medical Center
14 shared publicationsXiaohua Zhu
Department of Hematology/Oncology Children's Hospital of Fudan University, National Children's Medical Center Shanghai China
10 shared publicationsWenjin Jiang
Department of Hematology, Children’s Hospital of Fudan University, National Children’s Medical Center
9 shared publicationsYi Yu
Department of Hematology and Oncology Children's Hospital of Fudan University, National Children's Medical Center Shanghai China
9 shared publications- Hongsheng Wang
Department of Hematology/Oncology Children's Hospital of Fudan University, National Children's Medical Center Shanghai China
8 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1974352
Population pharmacokinetics and model-informed precision dosing of busulfan in Chinese pediatric allogeneic hematopoietic stem cell transplantation: a prospective real-world cohort study
Background: Busulfan is a cornerstone of conditioning regimens for pediatric allogeneic hematopoietic stem cell transplantation (HSCT), yet its narrow therapeutic index and high pharmacokinetic variability necessitate individualized dosing. This study aimed to develop and evaluate a population pharmacokinetic (PopPK) model for busulfan in Chinese pediatric allogeneic HSCT recipients, characterize the exposure-response relationship, and establish a model-informed precision dosing (MIPD) strategy for clinical implementation. Methods: This prospective, single-center study was conducted at Children’s Hospital of Fudan University between August 2020 and January 2026. Plasma busulfan concentrations were quantified using a validated HPLC-MS/MS. PopPK analysis was performed using nonlinear mixed-effects modeling. The association between busulfan exposure (AUC 0–6h ) and clinical outcomes was evaluated using logistic regression. Monte Carlo simulations were performed to derive an age- and body weight-stratified dosing regimen, and a closed-loop MIPD workflow was developed for clinical implementation. Results: A total of 290 pediatric HSCT recipients contributed 1543 busulfan concentration measurements. A two-compartment model with first-order elimination adequately characterized busulfan pharmacokinetics. Body weight and age were significant determinants of clearance. For a 70 kg reference individual, the population estimates of clearance and central volume of distribution were 12.4 L/h and 40.8 L, respectively. The model demonstrated good predictive performance in internal evaluation. Under empirical dosing, only 47.6% of patients achieved the target AUC 0–6h of 900–1350 μM min/L. Busulfan exposure (AUC 0–6h ) was not significantly associated with mortality (OR, 1.002; 95% CI, 1.000–1.004; P = 0.069) or acute graft-versus-host disease (OR, 1.001; 95% CI, 1.000–1.002; P = 0.161). Monte Carlo simulations supported an age- and body weight-stratified initial dosing regimen. A closed-loop MIPD workflow was established in which the initial dose is selected according to the simulated dosing regimen, followed by therapeutic drug monitoring and pharmacist-physician collaborative dose adjustment when AUC 0–6h falls outside the prespecified target range. Conclusion: A PopPK model with body weight and age as key determinants of busulfan clearance was developed and evaluated in a large real-world cohort of Chinese pediatric allogeneic HSCT recipients. The proposed MIPD framework provides a practical approach for optimizing busulfan therapy in this population.
- 26 October 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1974352
Open AccessPopulation pharmacokinetics and model-informed precision dosing of busulfan in Chinese pediatric allogeneic hematopoietic stem cell transplantation: a prospective real-world cohort study
Background: Busulfan is a cornerstone of conditioning regimens for pediatric allogeneic hematopoietic stem cell transplantation (HSCT), yet its narrow therapeutic index and high pharmacokinetic variability necessitate individualized dosing. This study aimed to develop and evaluate a population pharmacokinetic (PopPK) model for busulfan in Chinese pediatric allogeneic HSCT recipients, characterize the exposure-response relationship, and establish a model-informed precision dosing (MIPD) strategy for clinical implementation. Methods: This prospective, single-center study was conducted at Children’s Hospital of Fudan University between August 2020 and January 2026. Plasma busulfan concentrations were quantified using a validated HPLC-MS/MS. PopPK analysis was performed using nonlinear mixed-effects modeling. The association between busulfan exposure (AUC 0–6h ) and clinical outcomes was evaluated using logistic regression. Monte Carlo simulations were performed to derive an age- and body weight-stratified dosing regimen, and a closed-loop MIPD workflow was developed for clinical implementation. Results: A total of 290 pediatric HSCT recipients contributed 1543 busulfan concentration measurements. A two-compartment model with first-order elimination adequately characterized busulfan pharmacokinetics. Body weight and age were significant determinants of clearance. For a 70 kg reference individual, the population estimates of clearance and central volume of distribution were 12.4 L/h and 40.8 L, respectively. The model demonstrated good predictive performance in internal evaluation. Under empirical dosing, only 47.6% of patients achieved the target AUC 0–6h of 900–1350 μM min/L. Busulfan exposure (AUC 0–6h ) was not significantly associated with mortality (OR, 1.002; 95% CI, 1.000–1.004; P = 0.069) or acute graft-versus-host disease (OR, 1.001; 95% CI, 1.000–1.002; P = 0.161). Monte Carlo simulations supported an age- and body weight-stratified initial dosing regimen. A closed-loop MIPD workflow was established in which the initial dose is selected according to the simulated dosing regimen, followed by therapeutic drug monitoring and pharmacist-physician collaborative dose adjustment when AUC 0–6h falls outside the prespecified target range. Conclusion: A PopPK model with body weight and age as key determinants of busulfan clearance was developed and evaluated in a large real-world cohort of Chinese pediatric allogeneic HSCT recipients. The proposed MIPD framework provides a practical approach for optimizing busulfan therapy in this population.
- Open Access
- 30 September 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10)
Low‐Dose Cytarabine Plus G‐ CSF Induction in Pediatric M2 Acute Myeloid Leukemia: A Multicenter Study
This retrospective secondary analysis of the multicenter randomized CALS III‐AML18 trial evaluated the efficacy and safety of low‐dose chemotherapy (LDC) compared with standard‐dose chemotherapy (SDC) in children with M2 acute myeloid leukemia (AML‐M2). A total of 221 children were included, with 109 in the LDC arm and 112 in the SDC arm. The complete remission (CR)/CR with incomplete recovery (CRi) rates after induction I and II were 67.0% versus 70.5% ( p = 0.568) and 84.4% versus 89.3% ( p = 0.740), respectively. The 3 year overall survival (OS) rates were 81.2% ± 3.9% and 86.9% ± 3.3% in the LDC and SDC arms, respectively ( p = 0.304). The corresponding 3 year relapse‐free survival (RFS) rates were 82.0% ± 3.8% and 88.1% ± 3.1% ( p = 0.205), and the 3 year event‐free survival (EFS) rates were 62.1% ± 4.8% and 70.8% ± 4.4% ( p = 0.218). Among patients with KIT mutations, outcomes were poorer in the LDC arm than in the SDC arm, including 3 year OS (67.1% ± 8.7% vs. 91.5% ± 4.1%, p = 0.011), RFS (70.6% ± 7.8% vs. 87.5% ± 4.8%, p = 0.038), and EFS (49.2% ± 8.7% vs. 81.0% ± 5.7%, p = 0.002). Among patients who developed sepsis, grade 3–5 events were less frequent in the LDC arm than in the SDC arm (33.3% vs. 78.8%, p < 0.001). LDC was also associated with faster neutrophil and platelet recovery, lower transfusion requirements, and reduced treatment costs during induction. No statistically significant differences in remission or survival outcomes were observed between LDC and SDC, while the LDC regimen showed a lower treatment‐related burden. These findings support further evaluation of LDC as a toxicity‐sparing induction strategy in selected pediatric patients with AML‐M2. The poorer outcomes observed among patients with KIT mutations warrant caution when considering treatment de‐intensification in this subgroup.
- 30 September 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10)
Open AccessLow‐Dose Cytarabine Plus G‐ CSF Induction in Pediatric M2 Acute Myeloid Leukemia: A Multicenter Study
This retrospective secondary analysis of the multicenter randomized CALS III‐AML18 trial evaluated the efficacy and safety of low‐dose chemotherapy (LDC) compared with standard‐dose chemotherapy (SDC) in children with M2 acute myeloid leukemia (AML‐M2). A total of 221 children were included, with 109 in the LDC arm and 112 in the SDC arm. The complete remission (CR)/CR with incomplete recovery (CRi) rates after induction I and II were 67.0% versus 70.5% ( p = 0.568) and 84.4% versus 89.3% ( p = 0.740), respectively. The 3 year overall survival (OS) rates were 81.2% ± 3.9% and 86.9% ± 3.3% in the LDC and SDC arms, respectively ( p = 0.304). The corresponding 3 year relapse‐free survival (RFS) rates were 82.0% ± 3.8% and 88.1% ± 3.1% ( p = 0.205), and the 3 year event‐free survival (EFS) rates were 62.1% ± 4.8% and 70.8% ± 4.4% ( p = 0.218). Among patients with KIT mutations, outcomes were poorer in the LDC arm than in the SDC arm, including 3 year OS (67.1% ± 8.7% vs. 91.5% ± 4.1%, p = 0.011), RFS (70.6% ± 7.8% vs. 87.5% ± 4.8%, p = 0.038), and EFS (49.2% ± 8.7% vs. 81.0% ± 5.7%, p = 0.002). Among patients who developed sepsis, grade 3–5 events were less frequent in the LDC arm than in the SDC arm (33.3% vs. 78.8%, p < 0.001). LDC was also associated with faster neutrophil and platelet recovery, lower transfusion requirements, and reduced treatment costs during induction. No statistically significant differences in remission or survival outcomes were observed between LDC and SDC, while the LDC regimen showed a lower treatment‐related burden. These findings support further evaluation of LDC as a toxicity‐sparing induction strategy in selected pediatric patients with AML‐M2. The poorer outcomes observed among patients with KIT mutations warrant caution when considering treatment de‐intensification in this subgroup.
- 7 September 2026
- Published by Elsevier in Cell Stem Cell
- Vol. 33 (10) , 1597-1609.e4
Clinical base editing for β-hemoglobinopathies across different genetic backgrounds
- 7 September 2026
- Published by Elsevier in Cell Stem Cell
- Vol. 33 (10) , 1597-1609.e4
Clinical base editing for β-hemoglobinopathies across different genetic backgrounds
- Open Access
- 26 August 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1941475
Bridging the medical cliff: a paediatric–adult continuity of care model for 2,341 young adults with rare diseases in China
Introduction: Adolescents and young adults with rare diseases face a “medical cliff” when they age out of paediatric services, losing established care relationships and disease-specific expertise. Most rare diseases begin in childhood, since 69.9% of catalogued rare diseases are of exclusively paediatric onset. The problem is acute in China, where an estimated 20 million people live with a rare disease and systematic transitional care pathways remain largely absent. Methods: We describe the development and implementation of an integrated paediatric–adult continuity of care model for rare diseases, the adult population it serves, and early operational indicators of its feasibility. This retrospective, descriptive analysis used clinical service data from the Children's Hospital of Fudan University, Shanghai, over a 38-month window (3 January 2023–25 February 2026); the model was implemented from September 2023. Its four components were expanded treatment authority with proactive management; a multidisciplinary paediatric–adult joint clinic; proactive follow-up with dynamic evaluation; and medical social work with psychosocial support. The programme admits patients aged 18–35 years. Results: In total, 2,341 patients aged ≥18 years generated 4,847 outpatient, emergency, and inpatient encounters (mean age at first encounter 22.7 ± 5.9 years; 51.7% female). Annual encounter volumes rose from 240 in 2023 to 1,412 in 2024 and 2,628 in 2025, with a further 567 in January and February 2026. Return attendances accounted for 4,373 encounters (90.2%), and 843 patients (36.0%) attended more than once. The leading specialities were neurology (29.1%), hepatology (12.2%), and endocrinology (8.1%); most encounters were by Shanghai residents (54.8%). Discussion: Repeat attendance measures utilisation rather than adherence, and rising volumes likely reflect progressive implementation and growing awareness rather than model effectiveness. With enabling policies, paediatric hospitals can deliver continuous care for adult rare disease patients, although these indicators describe service activity rather than clinical or patient-reported outcomes. The model is best characterised as continuity of care delivered within paediatric services rather than as a conventional transition programme, and offers a replicable blueprint for health systems lacking established adult subspeciality services; cross-provincial health insurance portability remains the single most critical barrier to nationwide scale-up.
- 26 August 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1941475
Open AccessBridging the medical cliff: a paediatric–adult continuity of care model for 2,341 young adults with rare diseases in China
Introduction: Adolescents and young adults with rare diseases face a “medical cliff” when they age out of paediatric services, losing established care relationships and disease-specific expertise. Most rare diseases begin in childhood, since 69.9% of catalogued rare diseases are of exclusively paediatric onset. The problem is acute in China, where an estimated 20 million people live with a rare disease and systematic transitional care pathways remain largely absent. Methods: We describe the development and implementation of an integrated paediatric–adult continuity of care model for rare diseases, the adult population it serves, and early operational indicators of its feasibility. This retrospective, descriptive analysis used clinical service data from the Children's Hospital of Fudan University, Shanghai, over a 38-month window (3 January 2023–25 February 2026); the model was implemented from September 2023. Its four components were expanded treatment authority with proactive management; a multidisciplinary paediatric–adult joint clinic; proactive follow-up with dynamic evaluation; and medical social work with psychosocial support. The programme admits patients aged 18–35 years. Results: In total, 2,341 patients aged ≥18 years generated 4,847 outpatient, emergency, and inpatient encounters (mean age at first encounter 22.7 ± 5.9 years; 51.7% female). Annual encounter volumes rose from 240 in 2023 to 1,412 in 2024 and 2,628 in 2025, with a further 567 in January and February 2026. Return attendances accounted for 4,373 encounters (90.2%), and 843 patients (36.0%) attended more than once. The leading specialities were neurology (29.1%), hepatology (12.2%), and endocrinology (8.1%); most encounters were by Shanghai residents (54.8%). Discussion: Repeat attendance measures utilisation rather than adherence, and rising volumes likely reflect progressive implementation and growing awareness rather than model effectiveness. With enabling policies, paediatric hospitals can deliver continuous care for adult rare disease patients, although these indicators describe service activity rather than clinical or patient-reported outcomes. The model is best characterised as continuity of care delivered within paediatric services rather than as a conventional transition programme, and offers a replicable blueprint for health systems lacking established adult subspeciality services; cross-provincial health insurance portability remains the single most critical barrier to nationwide scale-up.
- 29 July 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (9) , e70463
Cyclosporine Stabilized the Hemoglobin Level in Children With Novel Compound Heterozygous Mutations in the LIG1 Gene: A Single Case Report
- 29 July 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (9) , e70463
Cyclosporine Stabilized the Hemoglobin Level in Children With Novel Compound Heterozygous Mutations in the LIG1 Gene: A Single Case Report
- Open Access
Prophylactic PEG-rhG-CSF Reduces Febrile Neutropenia in Pediatric Hematological Malignancies Compared with Daily rhG-CSF
Background: Febrile neutropenia (FN) is a major complication of chemotherapy in pediatric hematological malignancies. This study compared the efficacy and safety of prophylactic pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) versus daily short-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF). Methods: This single-center, open-label, randomized controlled trial was conducted at a tertiary children’s hospital in China. Pediatric patients (n = 86 cycles) or daily short-acting rhG-CSF (5 μg/kg/day, n = 45 cycles) after chemotherapy. The primary endpoint was FN incidence. Secondary endpoints included neutropenia incidence, FN duration, time to neutrophil recovery, blood product transfusions, hospital stay, and costs. Safety was assessed by monitoring adverse events (AEs) graded according to NCI CTCAE version 4.03. Results: Baseline characteristics were comparable between groups. PEG-rhG-CSF significantly reduced the incidence of FN (59.3% vs. 77.7%, OR 0.42 (0.18–0.97), p = 0.046) compared to daily rhG-CSF. The median time to neutrophil recovery was 9.8 days (95% CI: 8.1–10.7) in the PEG-rhG-CSF group and 10.3 days (95% CI: 8.6–11.1) in the control group (p = 0.45). No significant differences were observed in FN duration, transfusions, hospital stay, or costs. Subgroup analyses showed PEG-rhG-CSF significantly reduced FN in non-Hodgkin lymphoma (57.4% vs. 83.3%, OR 0.27 (0.08–0.89), p = 0.032). A total of 12 AEs (9.9% overall, mainly bone pain) were observed, with no significant difference between groups and no infection-related deaths. Conclusions: In this single-center, open-label trial, prophylactic single-dose PEG-rhG-CSF was associated with a lower incidence of FN compared to daily short-acting rhG-CSF. Safety profiles appeared broadly similar, but the sample size was insufficient to detect rare differences.
Open AccessProphylactic PEG-rhG-CSF Reduces Febrile Neutropenia in Pediatric Hematological Malignancies Compared with Daily rhG-CSF
Background: Febrile neutropenia (FN) is a major complication of chemotherapy in pediatric hematological malignancies. This study compared the efficacy and safety of prophylactic pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) versus daily short-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF). Methods: This single-center, open-label, randomized controlled trial was conducted at a tertiary children’s hospital in China. Pediatric patients (n = 86 cycles) or daily short-acting rhG-CSF (5 μg/kg/day, n = 45 cycles) after chemotherapy. The primary endpoint was FN incidence. Secondary endpoints included neutropenia incidence, FN duration, time to neutrophil recovery, blood product transfusions, hospital stay, and costs. Safety was assessed by monitoring adverse events (AEs) graded according to NCI CTCAE version 4.03. Results: Baseline characteristics were comparable between groups. PEG-rhG-CSF significantly reduced the incidence of FN (59.3% vs. 77.7%, OR 0.42 (0.18–0.97), p = 0.046) compared to daily rhG-CSF. The median time to neutrophil recovery was 9.8 days (95% CI: 8.1–10.7) in the PEG-rhG-CSF group and 10.3 days (95% CI: 8.6–11.1) in the control group (p = 0.45). No significant differences were observed in FN duration, transfusions, hospital stay, or costs. Subgroup analyses showed PEG-rhG-CSF significantly reduced FN in non-Hodgkin lymphoma (57.4% vs. 83.3%, OR 0.27 (0.08–0.89), p = 0.032). A total of 12 AEs (9.9% overall, mainly bone pain) were observed, with no significant difference between groups and no infection-related deaths. Conclusions: In this single-center, open-label trial, prophylactic single-dose PEG-rhG-CSF was associated with a lower incidence of FN compared to daily short-acting rhG-CSF. Safety profiles appeared broadly similar, but the sample size was insufficient to detect rare differences.
- 18 May 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (4) , 966-972
Combined Early Steroid Response and MRD Improve Risk Stratification in Pediatric Acute Lymphoblastic Leukemia: The CCCG ‐ ALL ‐2015 Study
Objective: To determine whether early dexamethasone response provides complementary prognostic information to minimal residual disease (MRD) and whether integrating both markers refines risk stratification in pediatric acute lymphoblastic leukemia (ALL). Methods: We retrospectively analyzed pediatric ALL patients treated at a single center according to the CCCG‐ALL‐2015 protocol. Day 5 steroid response was classified as dexamethasone good response (DGR) or dexamethasone poor response (DPR). Bone marrow MRD was measured on Days 19 and 46 of induction. A four‐quadrant classification was constructed by combining Day 5 steroid response with Day 46 MRD status (DGR/MRD−, DGR/MRD+, DPR/MRD−, DPR/MRD+) to evaluate event‐free survival (EFS) and cumulative incidence of relapse (CIR). Results: Among 312 patients, 220 were DGR and 92 were DPR. MRD negativity rates on Days 19 and 46 were significantly lower in DPR. Among 304 patients with paired MRD measurements, 181, 102, 18, and 3 patients were classified as D19−/D46−, D19+/D46−, D19+/D46+, and D19−/D46+, respectively, with progressively worse 5‐year EFS and increasing 5‐year CIR. In the four‐quadrant analysis, EFS differed significantly across groups, and compared with DGR/MRD−, the other quadrants exhibited higher event risk. In multivariable Cox models, Day 46 MRD remained independently associated with inferior EFS (HR = 2.429, 95% CI: 1.286–4.590; p = 0.006). When the four‐quadrant classification was entered into the multivariable model (reference: DGR/MRD−), DGR/MRD+ (HR = 4.319, 95% CI 1.792–10.414; p = 0.001), DPR/MRD− (HR = 2.207, 95% CI: 1.253–3.888; p = 0.006), and DPR/MRD+ (HR = 3.718, 95% CI: 1.608–8.598; p = 0.002) were each associated with increased event risk. Conclusions: MRD kinetics identify patients with delayed clearance or persistent positivity at higher relapse risk. Integrating early steroid response with MRD using a four‐quadrant framework may complement MRD‐based assessment and further refine risk stratification by highlighting clinically meaningful discordant subgroups.
- 18 May 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (4) , 966-972
Combined Early Steroid Response and MRD Improve Risk Stratification in Pediatric Acute Lymphoblastic Leukemia: The CCCG ‐ ALL ‐2015 Study
Objective: To determine whether early dexamethasone response provides complementary prognostic information to minimal residual disease (MRD) and whether integrating both markers refines risk stratification in pediatric acute lymphoblastic leukemia (ALL). Methods: We retrospectively analyzed pediatric ALL patients treated at a single center according to the CCCG‐ALL‐2015 protocol. Day 5 steroid response was classified as dexamethasone good response (DGR) or dexamethasone poor response (DPR). Bone marrow MRD was measured on Days 19 and 46 of induction. A four‐quadrant classification was constructed by combining Day 5 steroid response with Day 46 MRD status (DGR/MRD−, DGR/MRD+, DPR/MRD−, DPR/MRD+) to evaluate event‐free survival (EFS) and cumulative incidence of relapse (CIR). Results: Among 312 patients, 220 were DGR and 92 were DPR. MRD negativity rates on Days 19 and 46 were significantly lower in DPR. Among 304 patients with paired MRD measurements, 181, 102, 18, and 3 patients were classified as D19−/D46−, D19+/D46−, D19+/D46+, and D19−/D46+, respectively, with progressively worse 5‐year EFS and increasing 5‐year CIR. In the four‐quadrant analysis, EFS differed significantly across groups, and compared with DGR/MRD−, the other quadrants exhibited higher event risk. In multivariable Cox models, Day 46 MRD remained independently associated with inferior EFS (HR = 2.429, 95% CI: 1.286–4.590; p = 0.006). When the four‐quadrant classification was entered into the multivariable model (reference: DGR/MRD−), DGR/MRD+ (HR = 4.319, 95% CI 1.792–10.414; p = 0.001), DPR/MRD− (HR = 2.207, 95% CI: 1.253–3.888; p = 0.006), and DPR/MRD+ (HR = 3.718, 95% CI: 1.608–8.598; p = 0.002) were each associated with increased event risk. Conclusions: MRD kinetics identify patients with delayed clearance or persistent positivity at higher relapse risk. Integrating early steroid response with MRD using a four‐quadrant framework may complement MRD‐based assessment and further refine risk stratification by highlighting clinically meaningful discordant subgroups.
- 2 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (8) , 978.e1-978.e15
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in X-Linked Hyper IgM Syndrome: A Multicenter Chinese Cohort Study from CCBMT
- 2 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (8) , 978.e1-978.e15
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in X-Linked Hyper IgM Syndrome: A Multicenter Chinese Cohort Study from CCBMT
- Open Access
- 17 April 2026
- Published by Springer Nature in BMC Palliative Care
- Vol. 25 (1)
Identifying palliative care needs in children with acute lymphoblastic leukemia: validation of the Chinese paediatric palliative screening scale (C-PaPaS)
Timely identification of pediatric palliative care (PPC) needs is essential to improving the quality of life for children with life-threatening illnesses.
- 17 April 2026
- Published by Springer Nature in BMC Palliative Care
- Vol. 25 (1)
Open AccessIdentifying palliative care needs in children with acute lymphoblastic leukemia: validation of the Chinese paediatric palliative screening scale (C-PaPaS)
Timely identification of pediatric palliative care (PPC) needs is essential to improving the quality of life for children with life-threatening illnesses.
- Open Access
- 13 February 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (3) , e70155
Infection Complications in Pediatric Patients With Inborn Errors of Immunity After Umbilical Cord Blood Transplantation: A Chinese Single‐Center Study
Background: Infection is a common complication following umbilical cord blood transplantation (UCBT), yet comprehensive data on pediatric patients with inborn errors of immunity (IEIs) in China are scarce. This study aimed to characterize infection profiles and their prognostic implications in this population. Methods: We retrospectively analyzed 165 IEIs patients undergoing UCBT between January 2015 and June 2020. The post‐transplantation period was divided into early (≤ 30 days) and middle (31–100 days) stages. Results: Within 100 days, 115 patients (69.7%) experienced 217 infection episodes. Engraftment failure was an independent predictor of infection risk within 100 days (OR = 2.97, p = 0.04). Low pre‐transplantation IgM levels and graft‐versus‐host disease (GVHD) prophylaxis with calcineurin inhibitors (CNIs) plus mycophenolate mofetil (MMF) increased early‐stage infection risks ( p < 0.05). Infections at the middle stage were correlated with Grade II–IV acute GVHD ( p = 0.03). Bloodstream infections (BSIs) were linked to CNIs combined with MMF and lower total nucleated cell counts in cord blood ( p < 0.05). Early‐stage infected group exhibited significantly poorer survival versus uninfected and middle‐stage groups ( p < 0.001). Patients without bacterial infections had higher survival rates than those with carbapenem‐resistant or non‐resistant infections ( p < 0.05). BSIs were associated with poor prognosis ( p < 0.05), while cytomegalovirus infection showed no significant survival impact ( p = 0.05). Conclusions: Infections are highly prevalent in IEIs children post‐UCBT, with early‐stage events and BSI portending poorer outcomes. These findings advocate for risk‐stratified surveillance and preemptive strategies in high‐risk subgroups. image
- 13 February 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (3) , e70155
Open AccessInfection Complications in Pediatric Patients With Inborn Errors of Immunity After Umbilical Cord Blood Transplantation: A Chinese Single‐Center Study
Background: Infection is a common complication following umbilical cord blood transplantation (UCBT), yet comprehensive data on pediatric patients with inborn errors of immunity (IEIs) in China are scarce. This study aimed to characterize infection profiles and their prognostic implications in this population. Methods: We retrospectively analyzed 165 IEIs patients undergoing UCBT between January 2015 and June 2020. The post‐transplantation period was divided into early (≤ 30 days) and middle (31–100 days) stages. Results: Within 100 days, 115 patients (69.7%) experienced 217 infection episodes. Engraftment failure was an independent predictor of infection risk within 100 days (OR = 2.97, p = 0.04). Low pre‐transplantation IgM levels and graft‐versus‐host disease (GVHD) prophylaxis with calcineurin inhibitors (CNIs) plus mycophenolate mofetil (MMF) increased early‐stage infection risks ( p < 0.05). Infections at the middle stage were correlated with Grade II–IV acute GVHD ( p = 0.03). Bloodstream infections (BSIs) were linked to CNIs combined with MMF and lower total nucleated cell counts in cord blood ( p < 0.05). Early‐stage infected group exhibited significantly poorer survival versus uninfected and middle‐stage groups ( p < 0.001). Patients without bacterial infections had higher survival rates than those with carbapenem‐resistant or non‐resistant infections ( p < 0.05). BSIs were associated with poor prognosis ( p < 0.05), while cytomegalovirus infection showed no significant survival impact ( p = 0.05). Conclusions: Infections are highly prevalent in IEIs children post‐UCBT, with early‐stage events and BSI portending poorer outcomes. These findings advocate for risk‐stratified surveillance and preemptive strategies in high‐risk subgroups. image